-
DEVELOPMENT AND VALIDATION OF AN AI-POWERED CLINICAL PHARMACIST ASSISTANT FOR PREDICTING ADVERSE DRUG REACTIONS IN INDIAN HOSPITALS
Mar 18, 2026, 21:38 PM -
A UNIQUE PATTERN OF AVERAGE SALES PRICE EROSION OF PEGFILGRASTIM FOLLOWING BIOSIMILAR ENTRY INTO THE US MARKET
Mar 18, 2026, 21:38 PM -
PATIENT CHARACTERISTICS AND HEALTH-RELATED QUALITY OF LIFE AMONG CONTROLLED AND UNCONTROLLED GOUT PATIENTS: EVIDENCE FROM THE MEPS DATABASE
Mar 18, 2026, 21:38 PM -
REAL-WORLD ECONOMIC BURDEN AND HEALTHCARE RESOURCE UTILIZATION AMONG DE NOVO MUSCLE-INVASIVE BLADDER CANCER (DNMIBC) PATIENTS IN ONTARIO, CANADA
Mar 18, 2026, 21:38 PM -
DOCUMENTATION OF ELECTRONIC NICOTINE DELIVERY SYSTEM, NICOTINE POUCH AND COMBUSTIBLE TOBACCO PRODUCT USE IN ELECTRONIC HEALTH RECORD CLINICAL NOTES
Mar 18, 2026, 21:38 PM -
THE ANALYTICAL FRAMEWORK OF CLINICAL TRIALS EVALUATING CLINICAL OUTCOMES OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL HEALTH INTERVENTIONS FOR MUSCULOSKELETAL DISORDERS: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
DEMOGRAPHIC DISPARITIES IN HPV VACCINE INITIATION AMONG KENTUCKY MEDICAID BENEFICIARIES
Mar 18, 2026, 21:38 PM -
VALIDATION EVIDENCE OF HEALTHCARE UTILISATION MEASURES FOR PAEDIATRIC POPULATIONS: A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
ALGORITHMIC FAIRNESS IN MACHINE LEARNING PREDICTION FOR LONG-TERM ADJUVANT ENDOCRINE THERAPY ADHERENCE AMONG BREAST CANCER SURVIVORS
Mar 18, 2026, 21:38 PM -
INTEGRATING SOCIAL DETERMINANTS OF HEALTH INTO GLP-1 VALUE ASSESSMENT: A PROPOSED DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS FRAMEWORK
Mar 18, 2026, 21:38 PM -
HEALTHCARE COST, RESOURCE USE, AND ECONOMIC MODELS OF CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER PATIENTS (MIBC)
Mar 18, 2026, 21:38 PM -
TRENDS IN THE USE OF REAL-WORLD EVIDENCE IN PRESS RELEASES ISSUED BY THE TOP 15 PHARMACEUTICAL COMPANIES
Mar 18, 2026, 21:38 PM -
ASSESSING THE IMPACT OF MISSINGNESS IN TREATMENT EFFECT MODIFIERS ON BIAS IN ANCHORED AND UNANCHORED MAIC AND STC
Mar 18, 2026, 21:38 PM -
BREAKTHROUGH THERAPY (BT) AND FAST TRACK (FT) DESIGNATIONS IN NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) TO FDA’S CENTER FOR DRUG EVALUATION AND RESEARCH (CDER), 2013-2025
Mar 18, 2026, 21:38 PM -
CHOOSING PUBLIC LLMS AND AI AGENTS FOR PATIENT OUTCOMES RESEARCH: PRACTICAL PROS/CONS AND GOVERNANCE IMPLICATIONS
Mar 18, 2026, 21:38 PM -
ETHICAL AI DEPLOYMENT IN HEOR
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS ANALYSIS OF INATICABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN CHINA
Mar 18, 2026, 21:38 PM -
EFFECT OF CHINESE HERBAL MEDICINE COMBINED WITH CONVENTIONAL ANTI-OSTEOPOROTIC MEDICATION ON FRACTURE RISK IN OLDER ADULTS WITH OSTEOPOROSIS: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF SGLT2I, GLP-1, AND METFORMIN ON CARDIOVASCULAR OUTCOMES IN ADULTS WITH SEVERE MENTAL ILLNESS
Mar 18, 2026, 21:38 PM -
THE BUDGET IMPACT OF INTRODUCING ZONGERTINIB INTO THE FORMULARY FOR TREATMENT-NAÏVE AND PRETREATED HER2-MUTANT ADVANCED NSCLC IN THE UNITED STATES
Mar 18, 2026, 21:38 PM
